Myriad Genetics Price To Earning vs. Current Valuation
| MYGN Stock | USD 16.17 0.46 2.93% |
| Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Gross Profit Margin | 0.94 | 0.81 |
|
|
For Myriad Genetics profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Myriad Genetics to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Myriad Genetics utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Myriad Genetics's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Myriad Genetics over time as well as its relative position and ranking within its peers.
Myriad |
Myriad Genetics' Revenue Breakdown by Earning Segment
Check out Correlation Analysis.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Myriad Genetics. If investors know Myriad will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Myriad Genetics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.28) | Revenue Per Share 9.205 | Quarterly Revenue Growth 0.112 | Return On Assets (0.05) | Return On Equity (0.16) |
The market value of Myriad Genetics is measured differently than its book value, which is the value of Myriad that is recorded on the company's balance sheet. Investors also form their own opinion of Myriad Genetics' value that differs from its market value or its book value, called intrinsic value, which is Myriad Genetics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Myriad Genetics' market value can be influenced by many factors that don't directly affect Myriad Genetics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Myriad Genetics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Myriad Genetics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Myriad Genetics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Myriad Genetics Current Valuation vs. Price To Earning Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Myriad Genetics's current stock value. Our valuation model uses many indicators to compare Myriad Genetics value to that of its competitors to determine the firm's financial worth. Myriad Genetics is rated below average in price to earning category among its peers. It is rated below average in current valuation category among its peers reporting about 46,114,662 of Current Valuation per Price To Earning. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Myriad Genetics' earnings, one of the primary drivers of an investment's value.Myriad Genetics' Earnings Breakdown by Geography
Myriad Current Valuation vs. Price To Earning
Price to Earnings ratio is typically used for current valuation of a company and is one of the most popular ratios that investors monitor daily. Holding a low PE stock is less risky because when a company's profitability falls, it is likely that earnings will also go down as well. In other words, if you start from a lower position, your downside risk is limited. There are also some investors who believe that low Price to Earnings ratio reflects the low pricing because a given company is in trouble. On the other hand, a higher PE ratio means that investors are paying more for each unit of profit.
Myriad Genetics |
| = | 31.95 X |
Generally speaking, the Price to Earnings ratio gives investors an idea of what the market is willing to pay for the company's current earnings.
Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Myriad Genetics |
| = | 1.47 B |
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
Myriad Current Valuation vs Competition
Myriad Genetics is rated below average in current valuation category among its peers. After adjusting for long-term liabilities, total market size of Health Care industry is now estimated at about 114.82 Billion. Myriad Genetics claims roughly 1.47 Billion in current valuation contributing just under 2% to equities under Health Care industry.
Myriad Genetics Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Myriad Genetics, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Myriad Genetics will eventually generate negative long term returns. The profitability progress is the general direction of Myriad Genetics' change in net profit over the period of time. It can combine multiple indicators of Myriad Genetics, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
| Last Reported | Projected for Next Year | ||
| Accumulated Other Comprehensive Income | -8 M | -7.6 M | |
| Operating Income | -144.6 M | -137.4 M | |
| Income Before Tax | -262.2 M | -249.1 M | |
| Total Other Income Expense Net | -117.2 M | -111.3 M | |
| Net Loss | -263.3 M | -250.1 M | |
| Income Tax Expense | -32.9 M | -31.2 M | |
| Net Loss | -263.3 M | -250.1 M | |
| Net Income Applicable To Common Shares | 202.7 M | 159.7 M | |
| Non Operating Income Net Other | 3.1 M | 3.5 M | |
| Net Interest Income | -400 K | -420 K | |
| Interest Income | 2.5 M | 2.4 M | |
| Change To Netincome | 64.3 M | 57.1 M | |
| Net Loss | (1.25) | (1.19) | |
| Income Quality | 0.85 | 0.81 | |
| Net Income Per E B T | 0.92 | 0.86 |
Myriad Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Myriad Genetics. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Myriad Genetics position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Myriad Genetics' important profitability drivers and their relationship over time.
Use Myriad Genetics in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Myriad Genetics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Myriad Genetics will appreciate offsetting losses from the drop in the long position's value.Myriad Genetics Pair Trading
Myriad Genetics Pair Trading Analysis
The ability to find closely correlated positions to Myriad Genetics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Myriad Genetics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Myriad Genetics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Myriad Genetics to buy it.
The correlation of Myriad Genetics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Myriad Genetics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Myriad Genetics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Myriad Genetics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your Myriad Genetics position
In addition to having Myriad Genetics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run SRI Sustainable Growth Thematic Idea Now
SRI Sustainable Growth
Socially responsible investments that include companies making a positive, sustainable or social impact and exclude those making a negative impact. The SRI Sustainable Growth theme has 47 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize SRI Sustainable Growth Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Correlation Analysis. To learn how to invest in Myriad Stock, please use our How to Invest in Myriad Genetics guide.You can also try the Top Crypto Exchanges module to search and analyze digital assets across top global cryptocurrency exchanges.
To fully project Myriad Genetics' future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Myriad Genetics at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Myriad Genetics' income statement, its balance sheet, and the statement of cash flows.